Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $1,060 | 2-4 weeks | |
5 mg | $3,150 | 2-4 weeks |
Description | Datopotamab deruxtecan (DS-1062; Dato-DXd) is an antibody-drug conjugate (ADC) that targets trophoblast cell surface antigen 2 (TROP2) and exhibits high antitumor activity. |
In vitro | Datopotamab deruxtecan (Dato-DXd; 100 μg/mL) specifically binds to TROP2 and is internalized into tumor cells, where it traffics to the lysosome, releasing Deruxtecan. This release causes DNA damage and induces apoptosis in TROP2-expressing tumor cells in vitro[1]. |
In vivo | Datopotamab deruxtecan (Dato-DXd; 6 mg/kg) demonstrates significant antitumor activity, inducing tumor regression in various TROP2-expressing xenograft models, including those from non-small cell lung cancer (NSCLC) patients. Safety evaluations in rats and cynomolgus monkeys reveal that Datopotamab deruxtecan has an acceptable safety profile [1]. |
Alias | Dato-DXd, DS-1062 |
Cas No. | 2238831-60-0 |
Storage | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.